World Vaccines Market 2011-2021

NEW YORK, Aug. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Vaccines Market 2011-2021

http://www.reportlinker.com/p0578539/World-Vaccines-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Do you want to know how the vaccines industry and market will develop from 2011? Our new report shows you potential revenues to 2021, discussing opportunities and prospects.

Our report gives you market forecasts to 2021 for vaccines in human healthcare. You will find revenue predictions at total world, submarket, product, company and national levels. Through our research and analysis we aim to save you time and help in your decisions.

You will see how products such as Prevnar, Pandemrix, Fluzone, Proquad/MMR-II/Varivax, Infanrix/Pediarix and Gardasil can perform to 2021. Our report shows revenue forecasts for leading vaccine brands.

In particular you will discover commercial prospects for GSK, Sanofi Pasteur, Merck & Co., Novartis and Pfizer, including revenue forecasts. We also discuss other vaccine producers.

Our report covers paediatric vaccines, influenza vaccines, other prophylactic vaccines, and therapeutic vaccines, with grouped forecasts. We discuss the R&D pipeline too, showing you where it is heading. 

We help you to assess the vaccine industry and market's strengths, weaknesses, trends and potential revenues to 2021. You will see what prospects the future holds.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions 

Our report shows you revenue forecasts, growth rates, market shares, competitive analysis, a SWOT/STEP review, R&D developments and opinions from our survey. We include 190 tables and charts and four research interviews (shown in the accompanying lists).

World Vaccines Market 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• You will discover revenue predictions to 2021 for the world vaccines market and its main components, seeing where the highest revenue growth will occur

• You will see revenue forecasts to 2021 for leading vaccine products, with discussions of market potential and competition

• You will find revenue forecasts to 2021 for leading national markets for vaccines (US, Japan, UK,Germany, France, Spain, Italy, China, India, Russiaand Brazil)

• You will assess leading companies providing vaccines, discovering their activities, outlooks and revenue prospects

• You will investigate competition and opportunities influencing the industry and market from 2011 onwards

• You will see what will stimulate and restrain the industry and market from 2011

• You will review vaccine technologies, assessing R&D potential

• You will investigate vaccination needs and sales opportunities

• You will analyse opportunities and challenges for established companies and those seeking to enter the vaccines market

• You will receive four interviews with authorities on vaccines - from industry and other organisations.

That mix of quantitative and qualitative analysis sets our report apart. We tackle crucial questions in the vaccines industry and market, aiming to save you time and effort.

Order our report now to gain industry and market analysis for vaccines

Our report is for everybody interested in market analysis, product development, sales and marketing for vaccines. We give you predictions and answers. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6.

Pricing:

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 Vaccines Market Review

1.2 Contents of this Report

1.3 Research and Analysis Methods

2. Introduction to the Vaccines Market

2.1 Vaccines are a Public Health Success Story

2.2 The Rise of the Vaccines Market

2.2.1 Vaccines and the New Pharmaceutical Business Models

2.2.2 The First 'Blockbuster Vaccine'

2.2.3 Technological and Regulatory Improvements

2.2.4 A Highly Desirable Market to Enter

2.3 How Vaccines Work: The Immune System and Natural Immunity

2.3.1 Vaccines Create Artificial Immunity

2.4 Types of Vaccine

2.4.1 Live, Attenuated Vaccines

2.4.2 Recombinant Live Vaccines

2.4.3 Inactivated Vaccines

2.4.4 Toxoid Vaccines

2.4.5 Subunit Vaccines

2.4.6 Conjugate Vaccines

2.4.7 Recombinant Subunit Vaccines

2.4.8 DNA Vaccines

2.4.9 Recombinant Vector Vaccines

2.5 Vaccine-Preventable Diseases

2.5.1 Chickenpox and Shingles

2.5.2 Cholera

2.5.3 Diphtheria

2.5.4 Haemophilus Influenzae Type B (Hib) Diseases

2.5.5 Hepatitis A

2.5.6 Hepatitis B

2.5.7 Human Papillomavirus (HPV) - Cervical Cancer

2.5.8 Influenza

2.5.8.1 Seasonal Influenza

2.5.8.2 Pandemic Influenza

2.5.8.3 Influenza Vaccination

2.5.9 Japanese Encephalitis

2.5.10 Measles

2.5.11 Neisseria Meningitidis - meningococcal diseases

2.5.12 Mumps

2.5.13 Pertussis

2.5.14 Polio

2.5.15 Rabies

2.5.16 Rotavirus Infections

2.5.17 Rubella

2.5.18 Streptococcus pneumoniae infections

2.5.19 Tetanus

2.5.20 Tick-Borne Encephalitis

2.5.21 Tuberculosis

2.5.22 Typhoid

2.5.23 Yellow Fever

2.6 Future Vaccine-Preventable Diseases

3. The Global Vaccines Market 2011-2021

3.1 The Global Vaccines Market was Worth $27.6bn in 2010

3.2 The Paediatric Sector Still Dominates the Vaccines Market

3.3 Balance of the Vaccines Market, 2011-2021

3.4 Paediatric Vaccines 2011-2021

3.4.1 Paediatric Vaccines Market Forecast, 2011-2021

3.4.2 Proprietary Products are Driving Paediatric Vaccine Growth

3.4.3 Important Unmet Needs Remain in Paediatric Vaccines

3.4.4 New Paediatric Vaccines Face Regulatory and Market-Access Challenges

3.5 Influenza Vaccines 2011-2021

3.5.1 Influenza Vaccines Market Forecast, 2011-2021

3.5.2 Growth Drivers for the Influenza Market

3.5.3 The Importance of Pandemic Influenza

3.5.4 The Challenge of Sustaining Growth in the Influenza Sector

3.6 Other Prophylactic Vaccines 2011-2021

3.6.1 Other Prophylactic Vaccines Market Forecast, 2011-2021

3.6.2 The Hepatitis Submarket

3.6.3 Vaccines for Cancer Prophylaxis

3.6.4 Prospects for Adult Vaccination

3.7 Therapeutic Vaccines 2011-2021

3.7.1 Therapeutic Vaccines Market Forecast, 2011-2021

3.7.2 The Potential for Therapeutic Vaccines

3.7.3 Targets for Therapeutic Vaccine Development

4. Leading National Markets 2011-2021

4.1 The US, Europe and Japan are the Largest Markets for Vaccines

4.2 The US

4.2.1 The US Vaccine Market Forecast 2011-2021

4.2.2 The US National Vaccination Plan

4.2.3 Issues in the US Vaccines Market

4.3 The EU Top Five

4.3.1 The EU Top Five Vaccine Market Forecast 2011-2021

4.3.2 Distribution of the EU Market, 2010

4.3.3 The German Vaccines Market 2011-2021

4.3.4 The French Vaccines Market 2011-2021

4.3.5 The UK Vaccines Market 2011-2021

4.3.6 The Spanish Vaccines Market 2011-2021

4.3.7 The Italian Vaccines Market 2011-2021

4.4 Japan 

4.4.1 The Japanese Vaccines Market 2011-2021

4.5 BRIC Nations

4.5.1 BRIC Nations: Vaccines Market Forecast 2011-2021

4.5.2 The Brazilian Vaccines Market 2011-2021

4.5.3 The Russian Vaccines Market 2011-2021

4.5.4 The Indian Vaccines Market 2011-2021

4.5.5 The Chinese Vaccines Market 2011-2021

4.6 Rest of the World: Vaccines Market 2011-2021

5.Top Companies in the Global Vaccines Market 2011-2021

5.1 Five Companies Control Three Quarters of the Market

5.2 GlaxoSmithKline: The Leading Player in the Vaccines Market 

5.2.1 Vaccine Sales Forecast for GlaxoSmithKline, 2011-2021

5.2.2 GlaxoSmithKline Vaccine Portfolio and Pipeline, 2011

5.3 Sanofi Pasteur: The Largest Company Exclusively Dedicated to Human Vaccines

5.3.1 Vaccine Sales Forecast for Sanofi Pasteur, 2011-2021

5.3.2 Sanofi Pasteur Vaccine Portfolio and Pipeline, 2011

5.4 Merck & Co: The Former Market Leader

5.4.1 Vaccine Sales Forecast for Merck & Co., 2011-2021

5.4.2 Merck & Co. Vaccine Portfolio and Pipeline, 2011

5.5 Novartis: Technological Innovators in the Vaccines Sector

5.5.1 Vaccine Sales Forecast for Novartis, 2011-2021

5.5.2 Novartis Vaccine Portfolio and Pipeline, 2011

5.6 Pfizer: Late Entry into the Vaccines Market

5.6.1 Vaccine Sales Forecast for Pfizer, 2011-2021

5.6.2 Pfizer Vaccine Portfolio and Pipeline, 2011

5.7 Companies in the Vaccines Market, 2011-2021 Summary

6. Top 15 Vaccine Products 2011-2021

6.1 Prevnar Remains the Leading Franchise 

6.2 Prevnar (Pfizer)

6.2.1 Sales Forecast for Prevnar, 2011-2021

6.2.2 Competition for Prevnar, 2011-2021

6.3 Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines (GlaxoSmithKline)

6.3.1 Sales Forecast for Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines, 2011-2021

6.3.2 Competition for Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines, 2011-2021

6.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi-Aventis)

6.4.1 Sales Forecast for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2011-2021

6.4.2 Competition for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2011-2021

6.5 Proquad/M-M-R II/Varivax (Merck & Co.)

6.5.1 Sales Forecast for Proquad/M-M-R II/Varivax, 2011-2021

6.5.2 Competition for Proquad/M-M-R II/Varivax, 2011-2021

6.6 Focetria/Celtura/Other Pandemic Influenza Vaccines (Novartis)

6.6.1 Sales Forecast for Focetria/Celtura/Other Pandemic Influenza Vaccines, 2011-2021

6.6.2 Competition for Focetria/Celtura/Other Pandemic Influenza Vaccines, 2011-2021

6.7 Engerix/Fendrix/Havrix/Twinrix/Ambirix (GlaxoSmithKline)

6.7.1 Sales Forecast for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2011-2021

6.7.2 Competition for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2011-2021

6.8 Infanrix/Pediarix (GlaxoSmithKline)

6.8.1 Sales Forecast for Infanrix/Pediarix, 2011-2021

6.8.2 Competition for Infanrix/Pediarix, 2011-2021

6.9 Pediacel/Pentacel/Pentavac/Pentaxim/Act-HIB/Others (Sanofi Pasteur)

6.9.1 Sales Forecast for Pediacel/Pentacel/Pentavac/Pentaxim/Act-HIB/Others, 2011-2021

6.9.2 Competition for Pediacel/Pentacel/Pentavac/Pentaxim/Act-HIB/Others, 2011-2021

6.10 Gardasil (Merck & Co.)

6.10.1 Sales Forecast for Gardasil, 2011-2021

6.10.2 Competition for Gardasil, 2011-2021

6.11 Menactra (Sanofi Pasteur)

6.11.1 Sales Forecast for Menactra, 2011-2021

6.11.2 Competition for Menactra, 2011-2021

6.12 RotaTeq (Merck & Co.)

6.12.1 Sales Forecast for RotaTeq, 2011-2021

6.12.2 Competition for RotaTeq, 2011-2021

6.13 Adacel (Sanofi Pasteur)

6.13.1 Sales Forecast for Adacel 2011-2021

6.13.2 Competition for Adacel, 2011-2021

6.14 Cervarix (GlaxoSmithKline)

6.14.1 Sales Forecast for Cervarix 2011-2021

6.14.2 Competition for Cervarix, 2011-2021

6.15 Fluarix/Flulaval (GlaxoSmithKline)

6.15.1 Sales Forecast for Fluarix/Flulaval 2011-2021

6.15.2 Competition for Fluarix/Flulaval 2011-2021

6.16 Rotarix (GlaxoSmithKline)

6.16.1 Sales Forecast for Rotarix 2011-2021

6.16.2 Competition for Rotarix 2011-2021

6.17 Leading Products in the Vaccines Market, 2011-2021 Summary

7. Top R&D Pipeline Opportunities in the Vaccines Sector

7.1 Bexsero (Novartis)

7.2 Menhibrix (GlaxoSmithKline)

7.3 Hexaxim (Sanofi Pasteur)

7.4 GSK 2186877A (GlaxoSmithKline)

7.5 Mosquirix (GlaxoSmithKline)

7.6 Nimenrix (GlaxoSmithKline) 

7.7 Simplirix (GlaxoSmithKline) 

7.8 Varicella Zoster Virus Vaccine (GlaxoSmithKline) 

7.9 V 503 (Merck & Co.) 

7.10 Imojev/Chimerivax-JE (Sanofi Pasteur) 

7.11 HIV Vaccine (Sanofi Pasteur)

7.12 Adenovirus Type 4 Vaccine, Adenovirus Type 7 Vaccine (Teva) 

7.13 Astoprotimut (GlaxoSmithKline) 

7.14 NicVAX (GlaxoSmithKline)

7.15 VaccinOVAR (Menarini) 

7.16 Mitizax (ALK-Abello)

7.17 Ragweed Vaccine (ALK-Abello)

7.18 Grazax (ALK-Abello)

7.19 Stimuvax (Merck KGaA)

7.20 Cancer Vaccine (Otsuka)

8. The Vaccines Market: Qualitative Analysis

8.1 Strengths

8.1.1 Vaccines are Successful

8.1.2 Combination Vaccines Have Made Administration Easier

8.1.3 The Industry is Strongly Consolidated, Yet Has Strong Biotech Involvement

8.1.4 There is Global Multilateral Investment in Vaccines

8.1.5 Blockbuster Pricing, Blockbuster Branding

8.1.6 There is No Generic Competition

8.2 Weaknesses

8.2.1 High Entry Barriers

8.2.2 Manufacturing Capacity Problems are Inherent in the Vaccines Market

8.2.3 Storage and Supply Difficulties

8.2.4 Variable Demand

8.3 Opportunities

8.3.1 New Indications

8.3.2 Bioterrorism

8.3.3 New Delivery Systems

8.3.4 The Growth of the Emerging Economies

8.3.5 New Technologies

8.4 Threats

8.4.1 The Controversy Surrounding Vaccines

8.4.2 Lack of Public Education Regarding Vaccines

8.4.3 Threat to Prices

9. Expert Opinions from Our Survey

9.1 Interview with Richard de Souza, CEO, Archimedes Pharma, and Dr Alan Smith, VP, R&D, Archimedes Development Limited

9.1.1 On the Constraints of Developing a Seasonal Influenza Vaccine

9.1.2 On the Principal Drivers and Restraints in the Influenza Vaccine Market

9.1.3 On Vaccination Coverage Rates in the Mature and Emerging Markets

9.1.4 On the Important Pipeline Developments

9.1.5 On Vaccine Development in the Emerging Markets

9.1.6 On the Future of Influenza Vaccines

9.2 Interview with Catherine Ammon, Business Continuity Coordinator, World Health Organization,Switzerland

9.2.1 On the Preparedness of Countries to Tackle a Pandemic

9.2.2 On the Current and Future Vaccination Rates

9.2.3 On the Most Important Unmet Need for Influenza Management

9.2.4 On the Principal Drivers and Restraints in the Vaccine Market

9.2.5 On the Common Seasonal Influenza Vaccines used in Switzerland

9.2.6 On the Pipeline Vaccines with Most Promise

9.2.7 Other Comments on Influenza Vaccines and their Future

9.3 Interview with Professor David Bishai, MD, PhD, MPH, Department of Population, Family and Reproductive Health and International Health, Johns Hopkins University, USA

9.3.1 On Strategies for Presenting Vaccination to General Public

9.3.2 On Advantages and Disadvantages of MDVs and PFSs

9.3.3 On Pandemic Preparedness and Intervention

9.4 Interview with Wayne Rudolph, Vice President, Corporate Development, BiondVax Pharmaceuticals

9.4.1 On Unmet Needs in Influenza Management

9.4.2 On the Principal Drivers and Restraints in the Influenza Market

9.4.3 On the Burden of Influenza Epidemics to the Economy

9.4.4 On Current Market for Influenza Vaccines

9.4.5 On Vaccination Rates in Mature and Emerging Markets

9.4.6 On Vaccine Development Capacity in US, EU and Emerging Markets

9.4.7 On BiondVax and Challenges of Developing a Universal Flu Vaccine

9.4.8 On BiondVax Technology for Vaccine Manufacture

9.4.9 On Progress of BiondVax's Universal Flu Vaccine

9.4.10 On Pipeline Products from BiondVax

9.4.11 On Pipeline Products from Other Manufacturers

9.4.12 On Pandemic Preparedness

10. Conclusions

10.1 The Vaccines Market is One of the Pharmaceutical Industry's Major Success Stories

10.2 The Paediatric Sector Remains the Largest, but Other Sectors are Gaining in Significance

10.3 The Emerging Markets are Highly Important to the Sector

10.4 The Market is Highly Consolidated

10.5 Concluding Remarks

List of Tables

Table 3.1 Global Vaccines Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015

Table 3.2 Global Vaccines Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021 

Table 3.3 Sectors within the Vaccines Market: Description, Sales ($bn), Market Shares (%), 2010

Table 3.4 Global Vaccine Market Submarkets: Sales ($bn), AGR (%), CAGR (%), 2010-2015 

Table 3.5 Global Vaccine Market Submarkets: Sales ($bn), AGR (%), CAGR (%), 2016-2021 

Table 3.6 Paediatric Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015 

Table 3.7 Paediatric Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021 

Table 3.8 Leading Paediatric Vaccine Products: Indications, Sales ($bn), Market Shares (%), 2010

Table 3.9 Influenza Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015 

Table 3.10 Influenza Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021 

Table 3.11 Leading Influenza Vaccine Products, Indications, Sales ($bn), Market Shares (%), 2010

Table 3.12 Other Prophylactic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015

Table 3.13 Other Prophylactic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021

Table 3.14 Leading Other Prophylactic Vaccine Products, Indications, Sales ($bn), Market Shares (%), 2010

Table 3.15 Therapeutic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2010-2015

Table 3.16 Therapeutic Vaccines, Market Forecast: Sales ($bn), AGR (%), CAGR (%), 2016-2021

Table 4.1 National Market Forecasts: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.2 National Market Forecasts: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.3 US Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.4 US Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.5 Objectives and Achievements to Date of 1994 US National Vaccine Plan, 2011

Table 4.6 EU Top Five Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2021

Table 4.7 EU Top Five Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.8 EU Top Five, National Vaccines Markets: Sales ($bn), Market Shares (%), 2010

Table 4.9 German Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015

Table 4.10 German Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021

Table 4.11 French Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015

Table 4.12 French Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021

Table 4.13 UK Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015

Table 4.14 UK Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021

Table 4.15 Spanish Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015

Table 4.16 Spanish Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021

Table 4.17 Italian Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2010-2015

Table 4.18 Italian Vaccines Market: Sales ($bn), AGR (%), CAGR (%) EU Market Shares (%), 2016-2021

Table 4.19 Japanese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.20 Japanese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.21 BRIC Nations Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.22 BRIC Nations Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.23 Brazilian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), BRIC Market Shares (%), 2010-2015

Table 4.24 Brazilian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.25 Russian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.26 Russian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.27 Indian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.28 Indian Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.29 Chinese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.30 Chinese Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 4.31 Rest of the World Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015

Table 4.32 Rest of the World Vaccines Market: Sales ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2021

Table 5.1 Leading Companies in the Vaccines Market: Sales ($bn), Market Shares (%), 2010

Table 5.2 GlaxoSmithKline Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015

Table 5.3 GlaxoSmithKline Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021

Table 5.4 GlaxoSmithKline Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Table 5.5 GlaxoSmithKline Vaccines Pipeline, 2011 

Table 5.6 Sanofi Pasteur Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015

Table 5.7 Sanofi Pasteur Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021

Table 5.8 Sanofi Pasteur Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Table 5.9 Sanofi Pasteur Vaccines Pipeline, 2011 

Table 5.10 Merck & Co. Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015

Table 5.11 Merck & Co. Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021

Table 5.12 Merck & Co. Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Table 5.13 Merck & Co. Vaccines Pipeline, 2011

Table 5.14 Novartis Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015

Table 5.15 Novartis Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021

Table 5.16 Novartis Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Table 5.17 Novartis Vaccines Pipeline, 2011 

Table 5.18 Pfizer Vaccines: Sales ($bn) AGR (%), CAGR (%), 2010-2015

Table 5.19 Pfizer Vaccines: Sales ($bn) AGR (%), CAGR (%), 2016-2021

Table 5.20 Leading Companies in the Vaccines Market: Sales ($bn) AGR (%), CAGR (%), Market Share (%), 2010-2015

Table 5.21 Leading Companies in the Vaccines Market: Sales ($bn) AGR (%), CAGR (%), Market Share (%), 2016-2021 

Table 6.1 Prevnar: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.2 Prevnar: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.3 Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.4 Sanofi Pasteur Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.5 Sanofi Pasteur Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.6 Proquad/M-M-R II/Varivax: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.7 Proquad/M-M-R II/ Varivax: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.8 Focetria/Celtura/Other Pandemic Influenza Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.9 GlaxoSmithKline Hepatitis Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.10 GlaxoSmithKline Hepatitis Vaccines: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.11 Infanrix/Pediarix: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.12 Infanrix/Pediarix: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.13 Sanofi Pasteur Paediatric Vaccines: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.14 Sanofi Pasteur Paediatric Vaccines: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.15 Gardasil: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.16 Gardasil: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.17 Menactra: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.18 Menactra: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.19 RotaTeq: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.20 RotaTeq Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.21 Adacel: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.22 Adacel: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.23 Cervarix: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.24 Cervarix: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.25 Fluarix/Flulaval: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.26 Fluarix/Flulaval: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.27 Rotarix: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.28 Rotarix: Sales ($m) AGR (%), CAGR (%), 2016-2021

Table 6.29 Leading Products in the Vaccines Market: Sales ($m) AGR (%), CAGR (%), 2010-2015

Table 6.30 Leading Products in the Vaccines Market: Sales ($m) AGR (%), CAGR (%), 2016-2021 

Table 8.1 SWOT Analysis of the Vaccines Market, 2011-2021

List of Figures

Figure 3.1 Global Vaccines Market Forecast: Sales ($bn), 2010-2015 

Figure 3.2 Global Vaccines Market Forecast: Sales ($bn), 2016-2021 

Figure 3.3 Sectors within the Vaccines Market, Sales ($bn), Market Shares (%), 2010

Figure 3.4 Global Vaccine Market Submarkets: Sales ($bn), 2010-2015 

Figure 3.5 Global Vaccine Market Submarkets: Sales ($bn), 2016-2021 

Figure 3.6 Paediatric Market Forecast: Sales ($bn), 2010-2015 

Figure 3.7 Paediatric Market Forecast: Sales ($bn), 2016-2021 

Figure 3.8 Leading Paediatric Vaccine Products: Sales ($bn), Market Shares (%), 2010

Figure 3.9 Influenza Market Forecast: Sales ($bn), 2010-2015 

Figure 3.10 Influenza Market Forecast: Sales ($bn), 2016-2021 

Figure 3.11 Leading Influenza Vaccine Products, Sales ($bn), Market Shares (%), 2010

Figure 3.12 Other Prophylactic Vaccines Market Forecast: Sales ($bn), 2010-2015 

Figure 3.13 Other Prophylactic Vaccines Market Forecast: Sales ($bn), 2016-2021 

Figure 3.14 Leading Other Prophylactic Vaccine Products, Sales ($bn), Market Shares (%), 2010

Figure 3.15 Therapeutic Vaccines Market Forecast: Sales ($bn), 2010-2015 

Figure 3.16 Therapeutic Vaccines Market Forecast: Sales ($bn), 2016-2021 

Figure 4.1 Leading National Market Forecasts: Sales ($bn), 2010-2015 

Figure 4.2 Leading National Market Forecasts: Sales ($bn), 2016-2021 

Figure 4.3 US Vaccine Market: Sales ($bn), 2010-2015 

Figure 4.4 US Vaccine Market: Sales ($bn), 2016-2021 

Figure 4.5 EU Top Five Vaccine Market: Sales ($bn), 2010-2015 

Figure 4.6 EU Top Five Vaccine Market: Sales ($bn), 2016-2021 

Figure 4.7 EU Top Five, National Vaccines Markets: Sales ($bn), Market Shares (%), 2010

Figure 4.8 German Vaccines Market: Sales ($bn), 2010-2015

Figure 4.9 German Vaccines Market: Sales ($bn), 2016-2021

Figure 4.10 French Vaccines Market: Sales, ($bn), 2010-2015

Figure 4.11 French Vaccines Market: Sales, ($bn), 2016-2021

Figure 4.12 UK Vaccines Market: Sales ($bn), 2010-2015

Figure 4.13 UK Vaccines Market: Sales ($bn), 2016-2021

Figure 4.14 Spanish Vaccines Market: Sales ($bn), 2010-2015

Figure 4.15 Spanish Vaccines Market: Sales ($bn), 2016-2021

Figure 4.16 Italian Vaccines Market: Sales ($bn), 2010-2015

Figure 4.17 Italian Vaccines Market: Sales ($bn), 2016-2021

Figure 4.18 Japanese Vaccines Market: Sales ($bn), 2010-2015

Figure 4.19 Japanese Vaccines Market: Sales ($bn), 2016-2021

Figure 4.20 BRIC Nations: Vaccines Market ($bn), 2010-2015

Figure 4.21 BRIC Nations: Vaccines Market: Sales ($bn), 2016-2021

Figure 4.22 Brazilian Vaccines Market: Sales ($bn), 2010-2015

Figure 4.23 Brazilian Vaccines Market: Sales ($bn), 2016-2021

Figure 4.24 Russian Vaccines Market: Sales ($bn), 2010-2015

Figure 4.25 Russian Vaccines Market: Sales ($bn), 2016-2021

Figure 4.26 Indian Vaccines Market: Sales ($bn), 2010-2015

Figure 4.27 Indian Vaccines Market: Sales ($bn), 2016-2021

Figure 4.28 Chinese Vaccines Market: Sales ($bn), 2010-2015

Figure 4.29 Chinese Vaccines Market: Sales ($bn), 2016-2021

Figure 4.30 Rest of the World Vaccines Market: Sales ($bn), 2010-2015

Figure 4.31 Rest of the World Vaccines Market: Sales ($bn), 2016-2021

Figure 5.1 Leading Companies in the Vaccines Market: Sales ($bn), Market Shares (%), 2010

Figure 5.2 GlaxoSmithKline Vaccines: Sales ($bn), 2010-2015

Figure 5.3 GlaxoSmithKline Vaccines: Sales ($bn), 2016-2021

Figure 5.4 GlaxoSmithKline Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Figure 5.5 Sanofi Pasteur Vaccines: Sales ($bn), 2010-2015

Figure 5.6 Sanofi Pasteur Vaccines: Sales ($bn), 2016-2021

Figure 5.7 Sanofi Pasteur Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Figure 5.8 Merck & Co. Vaccines: Sales ($bn), 2010-2015

Figure 5.9 Merck & Co. Vaccines: Sales ($bn), 2016-2021

Figure 5.10 Merck & Co. Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Figure 5.11 Novartis Vaccines: Sales ($bn), 2010-2015

Figure 5.12 Novartis Vaccines: Sales ($bn), 2016-2021

Figure 5.13 Novartis Top Vaccine Products: Sales ($m), Shares of Company Sales (%), 2010

Figure 5.14 Pfizer Vaccines: Sales ($bn), 2010-2015

Figure 5.15 Pfizer Vaccines: Sales ($bn), 2016-2021

Figure 6.1 Prevnar: Sales ($m), 2010-2015

Figure 6.2 Prevnar: Sales ($m), 2016-2021

Figure 6.3 Pandemrix/Prepandrix/Other Pandemic Influenza Vaccines: Sales ($m), 2010-2015

Figure 6.4 Sanofi Pasteur Influenza Vaccines: Sales ($m), 2010-2015

Figure 6.5 Sanofi Pasteur Influenza Vaccines Sales ($m), 2016-2021

Figure 6.6 Proquad/M-M-R II/Varivax Sales ($m), 2010-2015

Figure 6.7 Proquad/M-M-R II/Varivax: Sales ($m), 2016-2021

Figure 6.8 Focetria/Celtura/Other Pandemic Influenza Vaccines: Sales ($m), 2010-2015

Figure 6.9 GlaxoSmithKline Hepatitis Vaccines: Sales ($m), 2010-2015

Figure 6.10 GlaxoSmithKline Hepatitis Vaccines: Sales ($m), 2016-2021

Figure 6.11 Infanrix/Pediarix: Sales ($m), 2010-2015

Figure 6.12 Infanrix/Pediarix: Sales ($m), 2016-2021

Figure 6.13 Sanofi Pasteur Paediatric Vaccines: Sales ($m), 2010-2015

Figure 6.14 Sanofi Pasteur Paediatric Vaccines: Sales ($m), 2016-2021

Figure 6.15 Gardasil: Sales ($m), 2010-2015

Figure 6.16 Gardasil: Sales ($m), 2016-2021

Figure 6.17 Menactra: Sales ($m), 2010-2015

Figure 6.18 Menactra: Sales ($m), 2016-2021

Figure 6.19 RotaTeq: Sales ($m), 2010-2015

Figure 6.20 RotaTeq: Sales ($m), 2016-2021

Figure 6.21 Adacel Sales ($m), 2010-2015

Figure 6.22 Adacel: Sales ($m), 2016-2021

Figure 6.23 Cervarix: Sales ($m), 2010-2015

Figure 6.24 Cervarix: Sales ($m), 2016-2021

Figure 6.25 Fluarix/Flulaval: Sales ($m), 2010-2015

Figure 6.26 Fluarix/Flulaval: Sales ($m), 2016-2021

Figure 6.27 Rotarix: Sales ($m), 2010-2015

Figure 6.28 Rotarix: Sales ($m), 2016-2021

Companies Listed

Abbott

Acambis

Advisory Committee on Immunization Practices (ACIP) 

ALK-Abello

AlphaVax

American Home Products 

AstraZeneca

Avant Immunotherapeutics

Bavarian Nordic

Bayer Schering 

Baxter

Bharat Biotech

Biken Japan 

Bill and Melinda Gates Foundation

Binnopharm

Biocryst

Biogen Idec

Biological E

Bio-Manguinhos

Biomira

Butantan

Cell Control

Celltech

Chemo-Sero-Therapeutic Research Institute

China National Biotec Group 

Chinese Academy of Medical Sciences

Chiron

Coley Pharmaceutical

Commonwealth Serum Laboratories

Corixa

Crucell

CSL Biotherapies

Cytos

Daiichi Sankyo

Dendreon

Denka Seiken Company

European Medicines Agency (EMEA/EMA)

European Vaccine Manufacturers (EVM)

Evans Medica

Food and Drug Administration (US FDA) 

Fuso

GAVI 

GlaxoSmithKline

Global Alliance for Vaccines and Immunisation

Hualan Biological Engineering 

ID Biomedical

Institute for Genetic Research

Institute for Genomic Research 

Intercell

Italian National Health Service

Jiangsu Walvax Biotech Company

Johnson & Johnson 

Kitasato Institute

Lederle

Ludwig Institute for Cancer Research

Medeva

Medicare

MedImmune

Medirace

Menarini

Merck & Co.

Merck KGaA

Ministry of Health, Labour and Welfare (Japan)

Nabi Biopharmaceuticals

National Health Service (NHS)

National Institutes of Health (NIH)

National Institute for Clinical Excellence (NICE)

Novartis

Novavax

Oncothyreon

OncoTherapy Science

Otsuka

Oxford University

Pfizer

PowderJect

Protein Sciences

Ranbaxy

Roche

ROVI Pharmaceuticals

Sandoz

Sanofi

Sanofi Pasteur

Serum Institute

Shanghai Institute of Biological Sciences

Shantha Biotech 

Sinovac

Spanish Ministry of Health

Takeda

Thai Ministry of Public Health

UNICEF

UK Joint Committee on Vaccination and Immunisation

University of Massachusetts Medical School 

University of Queensland

University Hospital of Tubingen

US Advisory Committee on Immunization Practices

US Army

US Centers for Disease Control and Prevention

US Department of Defense

US Department of Health and Human Services 

Vaccine Manufacturers Association (India)

Vaxdesign

VaxInnate

VIVALis

Walter Reed Army Institute 

Wellcome Trust 

World Health Organization (WHO)

Wyeth

Zhejiang Tianyuan

To order this report:

Drug and Medication Industry: World Vaccines Market 2011-2021

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker